3//SEC Filing
CGI Cellerate RX, LLC 3
Accession 0001144204-19-015666
CIK 0000714256other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 6:48 PM ET
Size
11.0 KB
Accession
0001144204-19-015666
Insider Transaction Report
Form 3
CGI Cellerate RX, LLC
10% Owner
Holdings
Series F Convertible Preferred Stock
→ Common Stock (227,363,000 underlying)5% Convertible Promissory Note
Exercise: $0.09From: 2019-08-28Exp: 2021-03-01→ Common Stock (16,959,339 underlying)
Catalyst Rochal, LLC
10% Owner
Holdings
Series F Convertible Preferred Stock
→ Common Stock (227,363,000 underlying)5% Convertible Promissory Note
Exercise: $0.09From: 2019-08-28Exp: 2021-03-01→ Common Stock (16,959,339 underlying)
Gurasich Bradley J.
10% Owner
Holdings
Series F Convertible Preferred Stock
→ Common Stock (227,363,000 underlying)5% Convertible Promissory Note
Exercise: $0.09From: 2019-08-28Exp: 2021-03-01→ Common Stock (16,959,339 underlying)
Footnotes (3)
- [F1]Reflects 1,136,815 shares of Series F Convertible Preferred Stock ("Convertible <0x200E>Preferred Stock") owned of record by CGI Cellerate RX, LLC that are immediately convertible into 237,363,000 shares of Common Stock with equivalent <0x200E>voting rights. The Convertible Preferred Stock is convertible at any time, at the holder's election and has no expiration date. CGI Cellerate RX, LLC is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Gurasich is a manager of Catalyst Rochal, LLC. By virtue of these relationships, CGI Cellerate RX, LLC, Catalyst Rochal, LLC and, Mr. Gurasich may be deemed to share voting and dispositive control over the Common Stock issuable upon the conversion of the Convertible Preferred Stock. Catalyst Rochal, LLC and Mr. Gurasich disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.
- [F2]The Convertible Preferred Stock is convertible at on a 200 for 1 basis into fully paid and nonassessable shares of the Issuer's Common Stock.
- [F3]Reflects a $1,500,000.00 Convertible Promissory Note ("Note") from Wound Management Technologies, Inc. ("Issuer") to CGI Cellerate RX, LLC convertible into 16,959,339 shares of common stock of the Issuer at $0.09 per share as of December 31, 2018. CGI Cellerate RX, LLC is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Gurasich is a manager of Catalyst Rochal, LLC. By virtue of these relationships, CGI Cellerate RX, LLC, Catalyst Rochal, LLC and, Mr. Gurasich may be deemed to share voting and dispositive control over the Common Stock issuable upon the conversion of the Note. Catalyst Rochal, LLC and Mr. Gurasich disclaim beneficial ownership of any Common Stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.
Documents
Issuer
WOUND MANAGEMENT TECHNOLOGIES, INC.
CIK 0000714256
Entity typeother
IncorporatedTX
Related Parties
1- filerCIK 0001766396
Filing Metadata
- Form type
- 3
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 6:48 PM ET
- Size
- 11.0 KB